In the secondary recipients receiving 5 × 104 CML-BC BM cells, however, Evi1+/− CML-BC cells showed a significantly attenuated leukemogenic potential, whereas Evi1+/+ CML-BC retained the full capacity (Figure 5e). This evidence concerns the gene MECOM and breast cancer.